 | |
 | |
| Clinical data | |
|---|---|
| Other names | 4-(2-Methoxyethylthio)-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-(2-methoxyethylthio)phenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 6–8 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H21NO3S |
| Molar mass | 271.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
2C-T-13, also known as4-(2-methoxyethylthio)-2,5-dimethoxyphenethylamine, is apsychedelicphenethylamine of the2C family. It was presumably first synthesized byAlexander Shulgin and reported in his bookPiHKAL.[1]
The dose range of 2C-T-13 is 25 to 40 mg and its duration is approximately 6 to 8 hours according toAlexander Shulgin.[1] 2C-T-13 produces many closed-eye visuals and geometric patterns. It also produces slight visual distortion.[1]
The drug hasstructural properties similar tomescaline and other drugs in the 2C-T series, with the most closely related compounds being2C-T-7 and2C-T-21.[1]
2C-T-13 was first described in thescientific literature byAlexander Shulgin and colleagues in 1991.[2] Subsequently, it was described in greater detail by Shulgin in his 1991 bookPiHKAL (Phenethylamines I Have Known and Loved).[1]
As of October 31, 2016, 2C-T-13 is a controlled substance (Schedule III) in Canada.[3]
2C-T-13 is not scheduled in the United States, but possession and sales of 2C-T-13 could be prosecuted under theFederal Analog Act because of its structural similarities to2C-T-7.
